Fenwick Represents Elevation Oncology in Definitive Merger Agreement with Concentra Biosciences

Fenwick is representing Elevation Oncology, Inc. (Nasdaq: ELEV), an oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, in its definitive merger agreement with Concentra Biosciences.

Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock, plus one non-tradeable contingent value right, which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing, each pursuant to the contingent value rights agreement. More information can be obtained from the news announcement.

The Fenwick transaction team includes corporate partners David Michaels, Effie Toshav, Rob Freedman and Ryan Mitteness and associates Jordan Beals, Christian Choi, Anna Le and Max Krinsky; and executive compensation and employee benefits partner Marshall Mort and counsel Laura Mclntyre.